RxDoctor Payments Data

Camilla Davis

Physician Assistant · Tempe, AZNPI 1407159288

Payments from drug & device makers

$4,043in general payments, 2019–2025

Across 144 payments — averaging $28.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Boehringer Ingelheim$303
  • Amgen$301
  • GSK$244
  • Novo Nordisk$221
  • Kowa Pharmaceuticals America, Inc.$131
  • plus $1K from 36 others

What the payments were for

  • Consulting fees$80020%
  • Travel & lodging$3218%
  • Food & beverage$2,91072%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,043 in reported general payments places this provider in the 85th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$3,198
Medicare patients
22
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$41,444
EliquisApixaban23$36,277
Nurtec OdtRimegepant Sulfate12$25,088
JardianceEmpagliflozin12$16,223
FarxigaDapagliflozin Propanediol12$15,400
JanuviaSitagliptin Phosphate17$10,181
SymbicortBudesonide/Formoterol Fumarate16$4,209
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,644
Levothyroxine Sodium176$3,615
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,545
Liothyronine Sodium81$3,345
SynthroidLevothyroxine Sodium34$2,419
ProgesteroneProgesterone, Micronized62$2,168
Duloxetine Hcl24$1,708
Estradiol89$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$69$61,36535 claims
Novo NordiskOzempic$221$41,44421 claims
AstraZenecaFarxiga, Symbicort$33$19,60828 claims
Boehringer IngelheimJardiance$303$16,22312 claims
AbbVieSynthroid, Armour Thyroid$94$3,57349 claims
Acella Pharmaceuticals, LLCNp Thyroid$17$67616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →